Glucosamine pro-drug
OwnerFahkreddin Jamali, Kamalijit Kaur +1inventors
InventorsFahkreddin Jamali, Kamalijit Kaur, Mohammadhossien Gilzad
Life of this patent
Estimating the term…
Abstract
To develop glucosamine (GlcN) pro-drugs with properties superior to the presently available GlcN products, we have synthesized derivatives with improved pharmaceutical properties. The synthesized derivatives include peptide-GlcN ester and amide conjugates where the peptide portion consists of one or more amino acids. One such compound is (5-amino-3,4,6-trihydroxyoxan-2-yl)methyl 2-(2-aminoacetamido)-3-methylbutanoate or glycine-valine-COO-GlcN (GV-GlcN).7.
Claims4
A composition comprising a pharmaceutically acceptable salt or base of compounds chemically containing glucosamine (GlcN) with one or more amino acids attached at the amino or alcohol groups to form amide or ester of the amino-sugar with no ether linkage, wherein said compound is selected from the group consisting of a pharmaceutically accepted salt or base of (5-amino-3,4,6-trihydroxyoxan-2-yl)methyl 2-(2-aminoacetamido)-3-methylbutanoate;
- a pharmaceutically accepted salt or base of glycine-valine-COO-GlcN (GV-GlcN);
- and combinations thereof.
A method of treating any disease or condition for which glucosamine has been previously prescribed comprising administering an effective amount of a glucosamine pro-drug comprising a pharmaceutically accepted salt or base of (5-amino-3,4,6-trihydroxyoxan-2-yl)methyl 2-(2-aminoacetamido)-3-methylbutanoate or a pharmaceutically accepted salt or base of glycine-valine-COO-GlcN (GV-GlcN);
- or combinations thereof.
Dependencies are inferred from the claim text.